Massachusetts Financial Services Co. MA Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Massachusetts Financial Services Co. MA boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 7.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 76,502,238 shares of the biopharmaceutical company's stock after acquiring an additional 5,350,381 shares during the period. Massachusetts Financial Services Co. MA owned 1.35% of Pfizer worth $2,029,604,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its holdings in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its holdings in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after acquiring an additional 159,984 shares during the last quarter. NFJ Investment Group LLC increased its stake in shares of Pfizer by 12.8% in the third quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after purchasing an additional 43,719 shares in the last quarter. Copley Financial Group Inc. bought a new stake in shares of Pfizer in the third quarter valued at approximately $577,000. Finally, Zacks Investment Management boosted its holdings in shares of Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock worth $69,142,000 after acquiring an additional 235,243 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PFE shares. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Bank of America reissued a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Finally, UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Stock Up 0.8 %

Shares of PFE stock traded up $0.19 during trading hours on Wednesday, hitting $24.73. 41,783,008 shares of the company's stock traded hands, compared to its average volume of 39,243,727. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $140.26 billion, a price-to-earnings ratio of 17.54, a PEG ratio of 0.64 and a beta of 0.61. The stock's fifty day simple moving average is $25.98 and its two-hundred day simple moving average is $26.83. Pfizer Inc. has a 12-month low of $24.33 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.